Covered recipient · General Payments record
MADIHA A KHAN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$829.55
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $298.59 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $88.23 | 4 |
| Lilly USA, LLC | $49.45 | 3 |
| Corcept Therapeutics | $29.01 | 2 |
| Amgen Inc. | $26.43 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $26.40 | 1 |
| Acerta Pharma LLC | $17.40 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $16.84 | 1 |
| Novo Nordisk AS | $16.07 | 1 |
| Kowa Pharmaceuticals America, Inc. | $14.71 | 1 |
| Axsome Therapeutics, Inc. | $14.05 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.01 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104060902 | CMS |
| ABBVIE INC. | $18.87 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104060904 | CMS |
| ABBVIE INC. | $22.99 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104060906 | CMS |
| ABBVIE INC. | $31.36 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104060908 | CMS |
| Amgen Inc. | $13.24 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111618804 | CMS |
| Amgen Inc. | $13.19 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117296264 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.40 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104516028 | CMS |
| Axsome Therapeutics, Inc. | $14.05 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148300188 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $26.40 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086184382 | CMS |
| Corcept Therapeutics | $15.66 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117783149 | CMS |
| Corcept Therapeutics | $13.35 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117783155 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $16.84 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146755309 | CMS |
| Kowa Pharmaceuticals America, Inc. | $14.71 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113467429 | CMS |
| Lilly USA, LLC | $17.59 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135100174 | CMS |
| Lilly USA, LLC | $16.37 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135152994 | CMS |
| Lilly USA, LLC | $15.49 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135145479 | CMS |
| Novo Nordisk Inc | $16.07 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097452088 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.